The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Benefit of vitamin E, riluzole, and gababapentin in a transgenic model of familial amyotrophic lateral sclerosis
Abstract
Familial amyotrophic lateral sclerosis (FALS) has been linked in some families to dominant mutations of the SOD1 gene encoding Cu,Zn superoxide dismutase (Cu,Zn SOD). We have used a transgenic model of FALS based on expression of mutant human Cu,Zn SOD to explore the etiology and therapy of the genetic disease. Expression of mutant, but not wild‐type, human Cu,Zn SOD in mice places the brain and spinal cord under oxidative stress. This causes depletion of vitamin E, rather than the typical age‐dependent increase in vitamin E content as occurs in nontransgenic mice and in mice expressing wild‐type human Cu,Zn SOD. Dietary supplementation with vitamin E delays onset of clinical disease and slows progression in the transgenic model but does not prolong survival. In contrast, two putative inhibitors of the glutamatergic system, riluzole and gabapentin, prolong survival. However, riluzole did not delay disease onset. Thus, there was clear separation of effects on onset, progression, and survival by the three therapeutics tested. This suggests the hypothesis that oxidative damage produced by the expression of mutant Cu,Zn SOD causes slow or weak excitotoxicity that can be inhibited in part by altering glutamate release or biosynthesis presynaptically.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A., Donaldson, D., Goto, J., O'Regan, J. P., Deng, H.-X., et al. (1993) · Nature · doi:10.1038/362059a0 · Cited by 7,062
Cited by
Oxidative stress in neurodegeneration: Cause or consequence?
Andersen, J. K. (2004) · Nature Medicine · doi:10.1038/nrn1434 · Cited by 1,869
Oxidative Stress in Neurodegenerative Diseases
Niedzielska, E., Smaga, I., Gawlik, M., Moniczewski, A., Stankowicz, P., Pera, J., & Filip, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-015-9337-5 · Cited by 800
The Role of Excitotoxicity in Neurodegenerative Disease
Doble, A. (1999) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00042-4 · Cited by 723
Self-citationNeuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
Klivenyi, P., Ferrante, R. J., Matthews, R. T., Bogdanov, M. B., Klein, A. M., Andreassen, O. A., Mueller, G., Wermer, M., Kaddurah-Daouk, R., & Beal, M. F. (1999) · Nature Medicine · doi:10.1038/6568 · Cited by 682
Animal models of neurodegenerative diseases
Dawson, T. M., Golde, T. E., & Lagier-Tourenne, C. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0236-8 · Cited by 576
Matthews, R. T., Yang, L., Browne, S., Baik, M., & Beal, M. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8892 · Cited by 557
Hüttemann, M., Pecina, P., Rainbolt, M., Sanderson, T. H., Kagan, V. E., Samavati, L., Doan, J. W., & Lee, I. (2011) · Mitochondrion · doi:10.1016/j.mito.2011.01.010 · Cited by 522
Design, power, and interpretation of studies in the standard murine model of ALS
Scott, S., Kranz, J. E., Cole, J., Lincecum, J. M., Thompson, K., Kelly, N., Bostrom, A., Theodoss, J., Al‐Nakhala, B. M., Vieira, F. G., et al. (2008) · Amyotrophic Lateral Sclerosis · doi:10.1080/17482960701856300 · Cited by 504
Inflammatory processes in amyotrophic lateral sclerosis
McGeer, P. L., & McGeer, E. G. (2002) · Muscle & Nerve · doi:10.1002/mus.10191 · Cited by 470
Bellingham, M. C. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00116.x · Cited by 388
Mattson, M. P. (1998) · Trends in Neurosciences · doi:10.1016/s0166-2236(97)01188-0 · Cited by 344
Mitochondrial Approaches for Neuroprotection
Chaturvedi, R. K., & Beal, M. F. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.027 · Cited by 294
Foran, E., & Trotti, D. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2444 · Cited by 268
Yokota, T., Igarashi, K., Uchihara, T., Jishage, K.-I., Tomita, H., Inaba, A., Li, Y., Arita, M., Suzuki, H., Mizusawa, H., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261456098 · Cited by 261
Sexual differences in onset of disease and response to exercise in a transgenic model of ALS
Veldink, J. H., Bär, P. R., Joosten, E. A. J., Otten, M., Wokke, J. H. J., & van den Berg, L. H. (2003) · Neuromuscular Disorders · doi:10.1016/s0960-8966(03)00104-4 · Cited by 252
Carrı̀, M. T., Ferri, A., Cozzolino, M., Calabrese, L., & Rotilio, G. (2003) · Brain Research Bulletin · doi:10.1016/s0361-9230(03)00179-5 · Cited by 209
Antioxidant treatment for amyotrophic lateral sclerosis or motor neuron disease
Orrell, R. W., Lane, R. J., & Ross, M. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002829.pub4 · Cited by 98
Andreassen, O. A., Dedeoglu, A., Friedlich, A., Ferrante, K. L., Hughes, D., Szabo, C., & Beal, M. F. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7633 · Cited by 96
Mitochondrial Dysfunctions: A Red Thread across Neurodegenerative Diseases
Stanga, S., Caretto, A., Boido, M., & Vercelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103719 · Cited by 90
Zhang, H., Andrekopoulos, C., Joseph, J., Crow, J., & Kalyanaraman, B. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.02.038 · Cited by 59
Metadata
- Authors
- Gurney, M. E., Cutting, F. B., Zhai, P., Doble, A., Taylor, C. P., Andrus, P. K., & Hall, E. D.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 1996-02
- Volume
- 39
- Issue
- 2
- Pages
- 147-157
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W2068201081
- Cited by
- 645
- References
- 1
- FWCI
- 36.08
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
